These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 21516557)
21. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. Wang SJ; Hung HM; O'Neill R J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573 [TBL] [Abstract][Full Text] [Related]
23. Editors' Introduction to this Special Issue on Club Drug Epidemiology. Fendrich M; Johnson TP Subst Use Misuse; 2005; 40(9-10):1179-84. PubMed ID: 16048811 [No Abstract] [Full Text] [Related]
24. Pharmacogenomics: the implementation phase. Sadee W AAPS PharmSci; 2002; 4(2):E5. PubMed ID: 12141268 [TBL] [Abstract][Full Text] [Related]
25. New Zealand's drug development industry--strengths and opportunities. Lockhart MM; Babar ZU; Garg S N Z Med J; 2010 Jun; 123(1317):52-8. PubMed ID: 20657631 [TBL] [Abstract][Full Text] [Related]
26. Bibliography-Editors' selection of current word literature. Coron Artery Dis; 2011 Jan; 22(1):45-7. PubMed ID: 21160292 [No Abstract] [Full Text] [Related]
27. Bibliography-Editors' selection of current world literature. Coron Artery Dis; 2010 Nov; 21(7):441-3. PubMed ID: 20924227 [No Abstract] [Full Text] [Related]
28. Integrating genomics across drug discovery and development. Debouck C Toxicol Lett; 2009 Apr; 186(1):9-12. PubMed ID: 18930125 [TBL] [Abstract][Full Text] [Related]
29. Guest editors' note on the special issue Diao G; Mao L; Jin F; Lin J J Biopharm Stat; 2022 Jul; 32(4):527-528. PubMed ID: 35776661 [No Abstract] [Full Text] [Related]
30. Bibliography--editors' selection of current world literature. Coron Artery Dis; 2009 Jan; 20(1):87-9. PubMed ID: 19060629 [No Abstract] [Full Text] [Related]
31. Bibliography--Editors' selection of current world literature. Coron Artery Dis; 2008 Dec; 19(8):645-7. PubMed ID: 19005300 [No Abstract] [Full Text] [Related]
32. Evaluation of policies to support drug development in New Zealand. Lockhart M; Babar ZU; Garg S Health Policy; 2010 Jul; 96(2):108-17. PubMed ID: 20170976 [TBL] [Abstract][Full Text] [Related]
33. Microarray analysis in drug discovery: an uplifting view of depression. Levy SE Sci STKE; 2003 Oct; 2003(206):pe46. PubMed ID: 14583588 [TBL] [Abstract][Full Text] [Related]
36. CNS drug development: part III: future directions. Preskorn SH J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894 [TBL] [Abstract][Full Text] [Related]
37. Bibliography--editors' selection of current world literature. Coron Artery Dis; 2009 Jun; 20(4):300-2. PubMed ID: 19440069 [No Abstract] [Full Text] [Related]
38. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress. Li Wan Po A J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998 [No Abstract] [Full Text] [Related]